Tamara van Donge

Chapter 6 110 References 1. Aranda JV, Thomas R. Systematic review: intravenous Ibuprofen in preterm newborns. Semin Perinatol. 2006;30(3):114-20. 2. Bose CL, Laughon MM. Patent ductus arteriosus: lack of evidence for common treatments. Arch Dis Child Fetal Neonatal Ed. 2007;92(6):F498-502. 3. Barst RJ, Gersony WM. The pharmacological treatment of patent ductus arteriosus. A review of the evidence. Drugs. 1989;38(2):249-66. 4. Mitra S, Florez ID, Tamayo ME, Mbuagbaw L, Vanniyasingam T, Veroniki AA, et al. Association of Placebo, Indomethacin, Ibuprofen, and Acetaminophen With Closure of Hemodynamically Significant Patent Ductus Arteriosus in Preterm Infants: A Systematic Review and Meta-analysis. JAMA. 2018;319(12):1221-38. 5. Ohlsson A, Walia R, Shah SS. Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants. Cochrane Database Syst Rev. 2020;2:CD003481. 6. Jensen TB, Kampmann JP, Trærup Andersen J. Patent ductus arteriosus closure: Why same-dose oral ibuprofen is superior to intravenous. Arch Dis Child Fetal Neonatal Ed. 105(3):F340. doi:10.1136/ archdischild-2019-317755 7. Madeleneau D, Aubelle MS, Pierron C, Lopez E, Patkai J, Roze JC, et al. Efficacy of a first course of Ibuprofen for patent ductus arteriosus closure in extremely preterm newborns according to their gestational age-specific Z-score for birth weight. PLoS One. 2015;10(4):e0124804. 8. Van Overmeire B, Touw D, Schepens PJ, Kearns GL, van den Anker JN. Ibuprofen pharmacokinetics in preterm infants with patent ductus arteriosus. Clin Pharmacol Ther. 2001;70(4):336-43. 9. Poon G. Ibuprofen lysine (NeoProfen) for the treatment of patent ductus arteriosus. Proc (Bayl Univ Med Cent). 2007;20(1):83-5. 10. Aranda JV, Varvarigou A, Beharry K, Bansal R, Bardin C, Modanlou H, et al. Pharmacokinetics and protein binding of intravenous ibuprofen in the premature newborn infant. Acta Paediatr. 1997;86(3):289-93. 11. Hirt D, Van Overmeire B, Treluyer JM, Langhendries JP, Marguglio A, Eisinger MJ, et al. An optimized ibuprofen dosing scheme for preterm neonates with patent ductus arteriosus, based on a population pharmacokinetic and pharmacodynamic study. Br J Clin Pharmacol. 2008;65(5):629-36. 12. Flint RB, Ter Heine R, Spaans E, Burger DM, de Klerk JCA, Allegaert K, et al. Simulation-based suggestions to improve ibuprofen dosing for patent ductus arteriosus in preterm newborns. Eur J Clin Pharmacol. 2018;74(12):1585-91. 13. Hynninen VV, Olkkola KT, Leino K, Lundgren S, Neuvonen PJ, Rane A, et al. Effects of the antifungals voriconazole and fluconazole on the pharmacokinetics of s-(+)- and R-(-)-Ibuprofen. Antimicrob Agents Chemother. 2006;50(6):1967-72. 14. Nada A, Bonachea EM, Askenazi DJ. Acute kidney injury in the fetus and neonate. Semin Fetal Neonatal Med. 2017;22(2):90-7. 15. Nakov N, Petkovska R, Ugrinova L, Kavrakovski Z, Dimitrovska A, Svinarov D. Critical development by design of a rugged HPLC-MS/MS method for direct determination of ibuprofen enantiomers in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2015;992:67-75. 16. Chan Kwong AHP, Calvier EAM, Fabre D, Gattacceca F, Khier S. Prior information for population pharmacokinetic and pharmacokinetic/pharmacodynamic analysis: overview and guidance with a focus on the NONMEM PRIOR subroutine. J Pharmacokinet Pharmacodyn. 2020;47(5):431-46.